Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | February 02, 2026 | February 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date February 02, 2026 · Filed February 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 167,935 |
Reported balance
After 2026-02-02 transaction · row 1
1 source rowRow 1 · 2026-02-02 · Sale · Disposed 14,814 · Balance 167,935 F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 2, 2026 23:59 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 14,814 | $5.09 | $75,412.15 |
DisclosureSEC source: 0001493152-26-004807 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,935 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 37,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003810 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,749 F1 · shares: All of the restricted stock will vest on January 26, 2027. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 5,176 | $5.82 | $30,147.09 |
DisclosureSEC source: 0001641172-25-018603 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,436 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.74 to $5.87 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-004754 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,612 F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e). F2 · shares: All of the restricted stock will vest on January 31, 2026. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 23:10 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-034058 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,511 F1 · kind: The acquisition was exempt pursuant to Rule 16b-3(d). F2 · shares: This stock grant represents the remainder of the 2024 annual grant to board of directors. This portion of the annual stock grant was withheld until all employees/management were allocated their shares and in order to enable onboarding of two new Board members. All of the restricted stock will vest on August 26, 2025. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 23,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026649 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,714 F1 · shares: All of the restricted stock will vest on July 8, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 58,689 | $4.62 | $271,143.18 |
DisclosureSEC source: 0001493152-23-021649 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,103 F1 · shares: All of the restricted stock will vest on June 14, 2024. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:32 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027041 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,414 F1 · shares: All of the restricted stock will vest on September 26, 2023. F2 · balance_after: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:52 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 98,168 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001493152-21-013130 · ownership.xml · derivative · entry 2 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,168 Underlying: Common Stock · 98,168 shares Expires 2031-05-25 F2 · derivative.exercise_date: All of the stock options will vest on November 25, 2021. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:52 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 77,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013130 · ownership.xml · nonDerivative · entry 1 Wuchterl Donald A. · CIK 0001857854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,181 F1 · shares: All of the restricted stock will vest on November 25, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.